Following publication of this article [1], concerns were raised about duplication of western blot images in Figs 1 and 6. Specifically,
- In Fig 1A the 2 h Actin panel for Control cells is a duplicate of the first three lanes of the Actin panel for Control cells in Fig 6A.
- In Fig 6B the Actin panel is incorrect and is a duplicate of the 18 h Actin panel for RA cells in Fig 6A of another PLOS ONE article [2] reporting a different experiment.
The corresponding author has stated that there were errors in selection of western blot images for Figs 1 and 6 as follows:
- In the originally published Fig 1A, the panels for Control cells are not taken from the same replicate experiment as the panels for the RA cells. A revised Fig 1 is provided in which all panels showing results for Control cells in 1A are replaced such that the revised figure shows the results for Control and RA cells from the same experiment.
thumbnail
Download:
*
PPT
PowerPoint slide
*
PNG
larger image
*
TIFF
original image
Fig 1. GXMGal effect on Treg cell response.
Activated PBMC (A and C) or purified CD4+ T cells (B) (both 5×106/ml) from Control and RA were incubated for 2, 18 and 72 h in the presence or absence (NS) of GXMGal (10 μg/ml) or MTX (10 ng/ml). After 2 and 18 h (A) or 18 h (B) of incubation, cell lysates were analyzed by western blotting. Membranes were incubated with Ab to FOXP3. Actin was used as an internal loading control. Normalization was shown as mean ± SEM of five independent experiments (A and B). *, p<0.05 (triplicate samples of 5 different Control and RA; RA treated vs untreated cells). Note that for both Control and RA cells the immunoblots at 18 h (A) share Actin loading control panels with the experiment shown in Fig 6A, as the same immunoblots were stripped and re-probed using different antibodies. Culture supernatants were collected after 2, 18 and 72 h to test TGF-β1 and IL-10 levels by specific ELISA assays. *, p<0.05 (triplicate samples of 7 different Control and RA; RA GXMGal-treated vs untreated cells); †, p<0.05 (triplicate samples of 7 different Control and RA; RA MTX-treated vs untreated cells) (C).
https://doi.org/10.1371/journal.pone.0247971.g001
- In the originally published Fig 6A, the panels for Control cells are not taken from the same replicate experiment as the panels for the RA cells. Additionally, the pSTAT3 and Actin panels for Control cells are incorrect and were taken from blots carried out at an earlier time point than stated (2 h as opposed to 18 h). In the originally
1. Pericolini E, Gabrielli E, Alunno A, Bartoloni Bocci E, Perito S, Chow S-K, et al. (2014) Functional Improvement of Regulatory T Cells from Rheumatoid Arthritis Subjects Induced by Capsular Polysaccharide Glucuronoxylomannogalactan. PLoS ONE 9(10): e111163. pmid:25338013
2. Pericolini E, Alunno A, Gabrielli E, Bartoloni E, Cenci E, Chow S-K, et al. (2013) The Microbial Capsular Polysaccharide Galactoxylomannan Inhibits IL-17A Production in Circulating T Cells from Rheumatoid Arthritis Patients. PLoS ONE 8(1): e53336. pmid:23308194
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021 The PLOS ONE Editors. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
The corresponding author has stated that there were errors in selection of western blot images for Figs 1 and 6 as follows: - In the originally published Fig 1A, the panels for Control cells are not taken from the same replicate experiment as the panels for the RA cells. Culture supernatants were collected after 2, 18 and 72 h to test TGF-β1 and IL-10 levels by specific ELISA assays. *, p<0.05 (triplicate samples of 7 different Control and RA; RA GXMGal-treated vs untreated cells); †, p<0.05 (triplicate samples of 7 different Control and RA; RA MTX-treated vs untreated cells) (C). https://doi.org/10.1371/journal.pone.0247971.g001 - In the originally published Fig 6A, the panels for Control cells are not taken from the same replicate experiment as the panels for the RA cells. (2014) Functional Improvement of Regulatory T Cells from Rheumatoid Arthritis Subjects Induced by Capsular Polysaccharide Glucuronoxylomannogalactan.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer